NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced that an abstract regarding the Company’s Fibrin Patch, a breakthrough biosurgery convergence product currently in development with Ethicon Inc., a Johnson & Johnson company, was presented by the U.S. Army at The American Association for the Surgery of Trauma (AAST) 2006 Annual Meeting, which took place September 29 – 30, 2006 in New Orleans, Louisiana.
